DC
TAK icon

Davenport & Co’s Takeda Pharmaceutical TAK Stock Holding History

Davenport & Co’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,416
Closed -$205K – 1205
2024
Q3 		$205K Sell
14,416
-121
-0.8% -$1.72K ﹤0.01% 1106
2024
Q2 		$188K Buy
14,537
+581
+4% +$7.69K ﹤0.01% 1083
2024
Q1 		$194K Buy
13,956
+76
+0.5% +$1.1K ﹤0.01% 1072
2023
Q4 		$198K Buy
13,880
+76
+0.6% +$1.08K ﹤0.01% 1019
2023
Q3 		$214K Sell
13,804
-198
-1% -$3.06K ﹤0.01% 969
2023
Q2 		$220K Buy
14,002
+2,555
+22% +$41.9K ﹤0.01% 975
2023
Q1 		$189K Buy
+11,447
New +$182K ﹤0.01% 992

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Davenport & Co's TAK Position: Q4 2024 in Review

Davenport & Co sold out of Takeda Pharmaceutical (TAK) in Q4 2024, closing a stake of 14,416 shares — an estimated $205K sold.

Davenport & Co first reported a position in TAK in Q1 2023 and held it in 7 quarters. The position peaked at $220K in Q2 2023. 299 funds tracked by Wall St. Rank hold TAK as of Q4 2024.

  • Davenport & Co reported no remaining Takeda Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • Davenport & Co sold 14,416 Takeda Pharmaceutical shares in Q4 2024, an estimated $205K.
  • Davenport & Co first reported a position in Takeda Pharmaceutical in Q1 2023 and held it in 7 quarters.
  • Davenport & Co's Takeda Pharmaceutical position peaked at $220K in Q2 2023.
  • 299 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2024.

Based on Davenport & Co's 13F filing for Q4 2024, filed 24 Jan 2025.